Study of Danicopan in Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH)
Status:
Completed
Trial end date:
2018-11-14
Target enrollment:
Participant gender:
Summary
The purpose of this study was to determine the safety and efficacy of ACH-0144471 (also known
as danicopan and ALXN2040) in currently untreated participants with PNH.